Tamoxifen in early breast cancer.

Lancet (London, England) ·Vol. 352 ·No. 9125 ·1998-08-01 ·Pages 404

Saibara T, Ogawa Y, Onishi S

Abstract

暂无摘要

MeSH Terms

Antineoplastic Agents, Hormonal/administration & dosage,adverse effects,therapeutic use Biomarkers/analysis Breast Neoplasms/drug therapy,pathology CD36 Antigens/analysis Estrogen Antagonists/administration & dosage,adverse effects,therapeutic use Fatty Liver/chemically induced,pathology Female Flow Cytometry Fluorescein-5-isothiocyanate Fluorescent Dyes Humans Tamoxifen/administration & dosage,adverse effects,therapeutic use

Chemicals

Antineoplastic Agents, Hormonal Biomarkers CD36 Antigens Estrogen Antagonists Fluorescent Dyes Tamoxifen Fluorescein-5-isothiocyanate

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Saibara T

Ogawa Y

Onishi S

Article Info

Journal

Lancet (London, England)

Abbr.

Lancet

ISSN

0140-6736

DOI

10.1016/S0140-6736(05)60502-8

Published

1998-08-01

Pages

404

Language

English

Region

England

NLM ID

2985213R

Subset

Corrections

CommentOn

PMID: 9605801

External Links

PubMed source DOI: 10.1016/S0140-6736(05)60502-8 View journal details

Analysis Services

Tamoxifen in early breast cancer.

Contact

WeChat Official Account